MedTrace Logo

Association Between Some Polymorphisms in Apelin/ Apelin Receptor Genes and Coronary Artery Disease in Syrian Patients

NCT05562687 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 223

Last updated 2026-04-01

No results posted yet for this study

Summary

The apelin-APJ signaling pathway has emerged as an important novel mediator of cardiovascular control and blood pressure homeostasis. Genetic variation in apelin and its receptors likely contributes to essential hypertension, in addition to a range of traditional risk factors. Thus, a study will be conducted on Syrian patients with hypertension and coronary artery disease to investigate some of the single polymorphisms in the apelin gene and its receptor that may be responsible for the development of these diseases, and to link the levels of this peptide and its receptor in the blood with these polymorphisms and the percentage of these diseases (as shown by many Modern Global Reference Studies).

Conditions

Sponsors & Collaborators

  • Damascus University

    lead OTHER

Principal Investigators

  • Hussam Eddin Mohammed Shibli, PhD · Damascus university, ASPU Al-Sham Private University

Eligibility

Min Age
30 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-15
Primary Completion
2022-01-05
Completion
2022-08-18

Countries

  • Syria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05562687 on ClinicalTrials.gov